Provided by Tiger Fintech (Singapore) Pte. Ltd.

Larimar Therapeutics, Inc.

2.68
+0.22008.94%
Post-market: 2.790.1100+4.10%18:47 EDT
Volume:1.23M
Turnover:3.30M
Market Cap:171.59M
PE:-1.80
High:2.78
Open:2.51
Low:2.47
Close:2.46
Loading ...

Larimar Therapeutics Inc. Conducted Annual Stockholders Meeting Virtually

Reuters
·
14 May

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), PTC Therapeutics (PTCT) and Larimar Therapeutics (LRMR)

TIPRANKS
·
06 May

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Humana (HUM) and Larimar Therapeutics (LRMR)

TIPRANKS
·
01 May

Larimar Therapeutics Q1 EPS $(0.46) Misses $(0.42) Estimate

Benzinga
·
30 Apr

BRIEF-Larimar Therapeutics Q1 Net Income USD -29.281 Million

Reuters
·
30 Apr

Larimar Therapeutics Q1 Basic EPS USD -0.46

THOMSON REUTERS
·
30 Apr

Larimar Therapeutics Q1 Operating Expenses USD 31.188 Million

THOMSON REUTERS
·
30 Apr

Larimar Therapeutics Reports First Quarter 2025 Financial Results

GlobeNewswire
·
30 Apr

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Simply Wall St.
·
28 Mar

Larimar Therapeutics Price Target Maintained With a $26.00/Share by Guggenheim

Dow Jones
·
25 Mar

Larimar Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
25 Mar

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Opthea Limited Sponsored ADR (OPT) and Larimar Therapeutics (LRMR)

TIPRANKS
·
25 Mar

William Blair Sticks to Their Buy Rating for Larimar Therapeutics (LRMR)

TIPRANKS
·
25 Mar

Wedbush Cuts Price Target on Larimar Therapeutics to $17 From $22, Maintains Outperform Rating

MT Newswires Live
·
24 Mar

Larimar Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
24 Mar

Larimar Therapeutics Q4 2024 GAAP EPS $(0.45) Misses $(0.32) Estimate, Cash $183.5M

Benzinga
·
24 Mar

BRIEF-Larimar Therapeutics Q4 Net Income USD -28.824 Million

Reuters
·
24 Mar

Larimar Therapeutics Q4 Basic EPS USD -0.45

THOMSON REUTERS
·
24 Mar

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
24 Mar

Larimar Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
14 Mar